Multiparametric Flow Cytometry in Mixed Phenotype Acute Leukemia

Sindhura Lakshmi Koulmane Laxminarayana, Nishika Madireddy, Chethan Manohar, Karthik Udupa

Research output: Contribution to journalArticle

Abstract

Mixed phenotype acute leukaemia (MPAL) is a diverse group of leukemia of ambiguous lineage diagnosed when blasts in peripheral blood and/or bone marrow have antigens of more than one lineage or a mosaic of blasts belonging to more than one lineage. Retrospective analysis of 218 consecutive cases of acute leukaemia diagnosed by multiparametric flow cytometry (FCM) was done. MPAL cases were identified in accordance with European Group for the Immunological Classification of Leukaemias Criteria and World Health Organization 2008/2016 guidelines for lineage assignment. Nine out of 218 (4.1%) cases were classified as MPAL. Eight out of nine patients (88.8%) were male and 4/9 (44.4%) were < 20 years of age. There were three cases of B/T and T/myeloid MPAL each. Two cases were B/myeloid MPAL and one case was chronic myeloid leukaemia (CML) in B/myeloid blast crisis. B/myeloid MPAL and CML in B/myeloid blast crisis cases were Philadelphia chromosome positive. The latter case had a complex karyotype as well. Seven cases were treated with acute lymphoblastic leukaemia treatment regimen; two of them achieved complete remission (CR). The patient with CML in B/myeloid blast crisis was treated with imatinib based regimen, attained CR, underwent allogenic bone marrow stem cell transplantation, but developed graft versus host disease. Five patients died due to complications of febrile neutropenia early in the course of treatment (62.5%). The last patient (B/T MPAL) refused therapy and was lost to follow-up. Early accurate diagnosis of MPAL requires FCM. It may be misdiagnosed if a limited panel of antibodies is used.

Original languageEnglish
Pages (from-to)451-458
Number of pages8
JournalIndian Journal of Hematology and Blood Transfusion
Volume35
Issue number3
DOIs
Publication statusPublished - 01-07-2019

Fingerprint

Flow Cytometry
Leukemia
Phenotype
Blast Crisis
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Philadelphia Chromosome
Febrile Neutropenia
Lost to Follow-Up
Stem Cell Transplantation
Graft vs Host Disease
Diagnostic Errors
Bone Marrow Transplantation
Karyotype
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Early Diagnosis
Therapeutics
Bone Marrow
Guidelines
Antigens
Antibodies

All Science Journal Classification (ASJC) codes

  • Hematology

Cite this

Koulmane Laxminarayana, Sindhura Lakshmi ; Madireddy, Nishika ; Manohar, Chethan ; Udupa, Karthik. / Multiparametric Flow Cytometry in Mixed Phenotype Acute Leukemia. In: Indian Journal of Hematology and Blood Transfusion. 2019 ; Vol. 35, No. 3. pp. 451-458.
@article{6b3060095ba24af084fa9a1737cc12c8,
title = "Multiparametric Flow Cytometry in Mixed Phenotype Acute Leukemia",
abstract = "Mixed phenotype acute leukaemia (MPAL) is a diverse group of leukemia of ambiguous lineage diagnosed when blasts in peripheral blood and/or bone marrow have antigens of more than one lineage or a mosaic of blasts belonging to more than one lineage. Retrospective analysis of 218 consecutive cases of acute leukaemia diagnosed by multiparametric flow cytometry (FCM) was done. MPAL cases were identified in accordance with European Group for the Immunological Classification of Leukaemias Criteria and World Health Organization 2008/2016 guidelines for lineage assignment. Nine out of 218 (4.1{\%}) cases were classified as MPAL. Eight out of nine patients (88.8{\%}) were male and 4/9 (44.4{\%}) were < 20 years of age. There were three cases of B/T and T/myeloid MPAL each. Two cases were B/myeloid MPAL and one case was chronic myeloid leukaemia (CML) in B/myeloid blast crisis. B/myeloid MPAL and CML in B/myeloid blast crisis cases were Philadelphia chromosome positive. The latter case had a complex karyotype as well. Seven cases were treated with acute lymphoblastic leukaemia treatment regimen; two of them achieved complete remission (CR). The patient with CML in B/myeloid blast crisis was treated with imatinib based regimen, attained CR, underwent allogenic bone marrow stem cell transplantation, but developed graft versus host disease. Five patients died due to complications of febrile neutropenia early in the course of treatment (62.5{\%}). The last patient (B/T MPAL) refused therapy and was lost to follow-up. Early accurate diagnosis of MPAL requires FCM. It may be misdiagnosed if a limited panel of antibodies is used.",
author = "{Koulmane Laxminarayana}, {Sindhura Lakshmi} and Nishika Madireddy and Chethan Manohar and Karthik Udupa",
year = "2019",
month = "7",
day = "1",
doi = "10.1007/s12288-019-01101-0",
language = "English",
volume = "35",
pages = "451--458",
journal = "Indian Journal of Hematology and Blood Transfusion",
issn = "0971-4502",
publisher = "Springer India",
number = "3",

}

Multiparametric Flow Cytometry in Mixed Phenotype Acute Leukemia. / Koulmane Laxminarayana, Sindhura Lakshmi; Madireddy, Nishika; Manohar, Chethan; Udupa, Karthik.

In: Indian Journal of Hematology and Blood Transfusion, Vol. 35, No. 3, 01.07.2019, p. 451-458.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Multiparametric Flow Cytometry in Mixed Phenotype Acute Leukemia

AU - Koulmane Laxminarayana, Sindhura Lakshmi

AU - Madireddy, Nishika

AU - Manohar, Chethan

AU - Udupa, Karthik

PY - 2019/7/1

Y1 - 2019/7/1

N2 - Mixed phenotype acute leukaemia (MPAL) is a diverse group of leukemia of ambiguous lineage diagnosed when blasts in peripheral blood and/or bone marrow have antigens of more than one lineage or a mosaic of blasts belonging to more than one lineage. Retrospective analysis of 218 consecutive cases of acute leukaemia diagnosed by multiparametric flow cytometry (FCM) was done. MPAL cases were identified in accordance with European Group for the Immunological Classification of Leukaemias Criteria and World Health Organization 2008/2016 guidelines for lineage assignment. Nine out of 218 (4.1%) cases were classified as MPAL. Eight out of nine patients (88.8%) were male and 4/9 (44.4%) were < 20 years of age. There were three cases of B/T and T/myeloid MPAL each. Two cases were B/myeloid MPAL and one case was chronic myeloid leukaemia (CML) in B/myeloid blast crisis. B/myeloid MPAL and CML in B/myeloid blast crisis cases were Philadelphia chromosome positive. The latter case had a complex karyotype as well. Seven cases were treated with acute lymphoblastic leukaemia treatment regimen; two of them achieved complete remission (CR). The patient with CML in B/myeloid blast crisis was treated with imatinib based regimen, attained CR, underwent allogenic bone marrow stem cell transplantation, but developed graft versus host disease. Five patients died due to complications of febrile neutropenia early in the course of treatment (62.5%). The last patient (B/T MPAL) refused therapy and was lost to follow-up. Early accurate diagnosis of MPAL requires FCM. It may be misdiagnosed if a limited panel of antibodies is used.

AB - Mixed phenotype acute leukaemia (MPAL) is a diverse group of leukemia of ambiguous lineage diagnosed when blasts in peripheral blood and/or bone marrow have antigens of more than one lineage or a mosaic of blasts belonging to more than one lineage. Retrospective analysis of 218 consecutive cases of acute leukaemia diagnosed by multiparametric flow cytometry (FCM) was done. MPAL cases were identified in accordance with European Group for the Immunological Classification of Leukaemias Criteria and World Health Organization 2008/2016 guidelines for lineage assignment. Nine out of 218 (4.1%) cases were classified as MPAL. Eight out of nine patients (88.8%) were male and 4/9 (44.4%) were < 20 years of age. There were three cases of B/T and T/myeloid MPAL each. Two cases were B/myeloid MPAL and one case was chronic myeloid leukaemia (CML) in B/myeloid blast crisis. B/myeloid MPAL and CML in B/myeloid blast crisis cases were Philadelphia chromosome positive. The latter case had a complex karyotype as well. Seven cases were treated with acute lymphoblastic leukaemia treatment regimen; two of them achieved complete remission (CR). The patient with CML in B/myeloid blast crisis was treated with imatinib based regimen, attained CR, underwent allogenic bone marrow stem cell transplantation, but developed graft versus host disease. Five patients died due to complications of febrile neutropenia early in the course of treatment (62.5%). The last patient (B/T MPAL) refused therapy and was lost to follow-up. Early accurate diagnosis of MPAL requires FCM. It may be misdiagnosed if a limited panel of antibodies is used.

UR - http://www.scopus.com/inward/record.url?scp=85061657991&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85061657991&partnerID=8YFLogxK

U2 - 10.1007/s12288-019-01101-0

DO - 10.1007/s12288-019-01101-0

M3 - Article

AN - SCOPUS:85061657991

VL - 35

SP - 451

EP - 458

JO - Indian Journal of Hematology and Blood Transfusion

JF - Indian Journal of Hematology and Blood Transfusion

SN - 0971-4502

IS - 3

ER -